| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $299K | — |
| Cost of Revenue | $38K | — |
| R&D Expense | $322K | -79.8% |
| SG&A Expense | $9.0M | +73.1% |
| Operating Income | -$9.0M | -32.8% |
| Pre-tax Income | -$28.7M | -125.1% |
| Income Tax | $0 | — |
| Net Income | -$28.7M | -125.1% |
| EPS (Basic) | -$8.81 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $5.5M | -68.9% |
| Current Assets | $25.4M | +43.2% |
| Total Assets | $25.8M | +45.7% |
| Current Liabilities | $1.8M | +78.8% |
| Total Liabilities | $3.9M | -64.1% |
| Stockholders' Equity | $21.1M | +259.0% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$6.4M | -30.9% |
| Investing Cash Flow | -$28.9M | -2789.5% |
| Financing Cash Flow | $23.1M | +551.7% |
| EPS (Diluted) | -$8.81 | -180.2% |